The government has advertised a Grade 7 post for a Pharmacovigilance Senior Assessor and Reporting Lead, focused on veterinary medicines already authorised for the UK market. Applications are being taken through Civil Service Jobs, and the closing date is 12 October 2026. Although presented as a vacancy notice, the post also shows where regulatory effort continues after a product reaches market: surveillance, clinical assessment and reporting rather than authorisation alone.
According to the notice, the job sits within the Pharmacovigilance team and centres on post-authorisation surveillance. Its stated purpose is to support ongoing assessment of the benefit-risk balance for veterinary medicinal products in use across the UK. That continuing review is a routine but important part of medicines regulation. Approval establishes the initial basis for use; pharmacovigilance tests whether that balance remains acceptable once products are being used more widely in practice.
The notice states that the appointment is for a veterinary surgeon. It also places responsibility on continuous monitoring of the efficacy and safety of veterinary medicinal products throughout their lifecycle, linking that work to the protection of animal, environmental and public health. For policy readers, that description matters because it places veterinary pharmacovigilance within health protection rather than treating it as a purely administrative function. The regulator still needs senior clinical judgement after authorisation, especially where evidence must be reviewed over time rather than at a single approval point.
The reporting lead element suggests the post extends beyond case assessment into how findings are documented and communicated within the regulatory system. Reliable reporting supports consistency in decision-making and helps maintain a clear record of how safety and efficacy evidence is being handled. For manufacturers, veterinary professionals and other users of the system, that reporting function matters because post-market oversight depends on information being translated into usable regulatory evidence. Without that step, surveillance activity is harder to turn into action.
The post is advertised at Grade 7 with a salary of £64,015 a year and access to the Civil Service pension scheme. The notice adds that the figure reflects a recent pay increase, while annual leave starts at 25 days. Those terms position the vacancy as a senior specialist appointment. In administrative terms, it combines clinical expertise with formal regulatory responsibility, which helps explain why recruitment at this level appears in a government news notice rather than as a routine internal advertisement.
Applications must be submitted through Civil Service Jobs, where the full job description is available. The recruitment window closes on 12 October 2026. As published, the announcement is brief. Read more closely, it offers a concise explanation of what the UK expects from veterinary medicines surveillance after approval: sustained assessment, formal reporting and ongoing review of the benefit-risk balance across a product's lifecycle.